The effect of astragaloside IV on doxorubicin-induced cardiotoxicity in young mice: exploring its cardioprotective effect during childhood tumor chemotherapy

Anthracyclines such as doxorubicin (DOX) are essential treatments in pediatric oncology but are highly associated with severe dose-dependent cardiotoxicity. The developing hearts of young patients are particularly vulnerable to DOX-induced oxidative damage, creating an urgent need for effective and safe cardioprotective strategies. This study aims to explore the protective efficacy of astragaloside IV (AS-IV) against DOX-induced cardiotoxicity in juvenile mice and investigate the underlying molecular mechanisms involving the silent information regulator 1 (Sirt1)/nuclear factor erythroid 2-related factor 2 (Nrf2) signaling axis and oxidative stress regulation.